Table 2 Countries with moderate endemic rates (2–10 cases/100,000 population per year)

African Region

South Africa

2000–2005

0.8–4

B in Western Cape

[22]

Eastern Mediterranean Region

No country in this region is in the moderate rate category

European Region

Belgium

1999–2010

2.9 (pre-vaccine)

B, C

[23, 24]

A conjugate vaccine for group C was introduced in 2002

0.89 (post-vaccine)

Denmark

1999–2010

1.19–3.5

B

[23, 24]

Greece

0.49–2.0

C

[23, 24]

A conjugate vaccine for group C introduced in 2001 in pediatric population[25]

Ireland

14.3 (pre-vaccine)

B, C

[23, 24]

A conjugate vaccine for group C was

2.19 (post-vaccine)

introduced in 2001

Iceland

7.6 (pre-vaccine)

B, C

[23, 24]

A conjugate vaccine for group C was

0.6 (post-vaccine)

introduced in 2002

Lithuania

2004–2010

1.4–2.6

*

[23, 24]

Luxemburg

1999–2010

0.2–5.68

*

[23, 24]

Malta

1994–2007

0.8–8.9

B, C

[26]

2 peaks in 2000 and 2006

Netherland

1999–2010

3.6 (pre-vaccine)

B, C

[23, 24]

A conjugate vaccine for group C was introduced in 2002

0.86 (post-vaccine)

Norway

1992–2010

0.8–4.6

B

[23, 27]

Portugal

2000–2010

0.74–3.0

B, C

[23, 28]

Spain

1999–2010

3.52 (pre-vaccine)

B, C

[23, 24]

A conjugate vaccine for group C introduced in 2001

0.88 (post vaccine)

Switzerland

1999–2004

1.16–2.36

C

[24]

A conjugate vaccine for group C introduced in 2005

Turkey

1997–2005

0.3–2.2

*

[28]

United Kingdom

1999–2010

5.4 (pre-vaccine)

B, C

[23, 24]

A conjugate vaccine for group C introduced in 1999

1.63 (post vaccine)

Region of the Americas

Brazil

1998–2006

1–4.5

B, now C

[19]

A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1990

Cuba

1998–2003

3.4-8.5 (pre-vaccine)

B

[29]

A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1987

<1 (post-vaccine)

South-East Asia Region

No country in this region is in the moderate rate category

Western Pacific Region

Australia

1995–2006

3.5–7.9 (pre-vaccine)

B

[30]

A conjugate vaccine for Serogroup C was introduced in 2003

1.4 (post-vaccine)